- ... syndrome, however, the result was not statistically significant. Additional studies have demonstrated similar survival outcomes ... that develop via the MSI pathway have more ...
- ... lOInlverslte Laval / edited by Marcel Martin, Louis Dlonne. - New York : Stratton Intercontinental Medical Book Corp., c!976. Ix, 182 p. : 111.-- (Symposia specialists medical books) 1. Immunotherapy - congresses 2. Neoplasms - therapy - congresses 3. Neoplasms - Immunology - congresses I. Dlonne, Louis, ...
- ... often with adjuvant intravesical therapy to destroy residual tumor cells using chemotherapeutic agents (e.g., ... Fatigue Syndrome Pacific Northwest ...
- ... abdominoperineal resection. Alternatively, patients may be treated with ... for patients with early-stage tumors smaller than 1 cm. It is also unclear ...
- ... the hypothesis that anaplasia evolves as a late event from a subpopulation of Wilms ... with responsiveness to therapy rather than to tumor aggressiveness. It is most ...
- ... efficacy of Iscador as an adjuvant long-term treatment after surgery for ... the use of immunotherapy was more frequent in the control group. Only ...
- NLM Digital Collections - Targeted immune modulators for rheumatoid arthritis: effectiveness & value : evidence reportPublication: Boston, MA : Institute for Clinical and Economic Review, March 10, 2017... 1) 0* patient who received rescue 2) 0 ... rate, Deaths (Trial Name) van Vollenhoven RF The New 1) PBO+MTX (n=106) Neoplasm benign, Serious infections, n (%) Discontinuation due to AEs, ...
- ... New drug regimens. Surgical resection of the primary tumor. New radiation therapy schedules and techniques (e.g., timing, three-dimensional ... review showed that 43% of patients treated with additional chemotherapy at the ... tumor have achieved successful palliation with endobronchial laser therapy ( ...
- ... reporting a significant benefit, with patients receiving the additional maintenance therapy having an increased event free ( Le Gouill et al. , 2014 ) and progression ...
- NLM Digital Collections - Hematologic malignancies : regulatory considerations for use of minimal residual disease in ...Publication: Silver Spring, MD : Center for Drug Evaluation and Research, January 2020... Topic Drug Approval Drug Development Drugs, Investigational Hematologic Neoplasms -- drug therapy Investigational New Drug Application Neoplasm, Residual Endpoint Determination Leukemia, Lymphocytic, ...
133 results